Abbisko IPO: Valuation Insights
Abbisko plans to raise $204m (net) at the mid-point of the IPO price range. Our valuation analysis suggests that the IPO price range is full and we...
331 Views
Abbisko (和誉) IPO: Fairly Valued for the Early Stage of Clinical Trials
We provide an update for Abbisko's book building. We run the deal through our ECM framework and provide our thoughts on the deal.
301 Views
Abbisko (和誉) Pre-IPO: Thoughts on Valuation
We provide forecast and valuation for the Abbisko's two core products, ABSK011 and ABSK091, as well as the SOTP valuation for the company's asset.
295 Views
Abbisko IPO: Some Products Show Good Potential but Too Early to Assess Their Success
Abbisko’s development pipeline is comprised of drugs that could become breakthrough therapies in the future, however, these product candidates are...
263 Views
ECM Weekly (26th September 2021) - Hanyu Med, Abbisko, SenseTime, ANE, Nykaa, Prudential HK
Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs.
387 Views